Proposal 2

NIKOLA CHAIRMAN ADDRESSES STOCKHOLDER QUESTIONS ON REVERSE SPLIT PROPOSAL IN DEFINITIVE PROXY STATEMENT

Retrieved on: 
Tuesday, April 30, 2024

PHOENIX, April 30, 2024 /PRNewswire/ -- In a recent social media post, Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, invited NKLA stockholders to submit questions related to the Proxy Statement filed earlier in the month. Steven Shindler, Chairman of the Board at Nikola, recorded a video addressing key questions about Proposal 2, which includes a reverse stock split.

Key Points: 
  • Steven Shindler, Chairman of the Board at Nikola, recorded a video addressing key questions about Proposal 2, which includes a reverse stock split.
  • The video addresses one of the five proposals to be voted on at the June 5, 2024, Annual Stockholder Meeting.
  • Among the questions addressed by Shindler were:
    What is a reverse split and how does it impact NKLA stockholders and the company?
  • Nikola invites NKLA stockholders to continue submitting questions , as ongoing communications are planned to provide answers to those most frequently asked.

XAI Octagon Floating Rate & Alternative Income Term Trust Adjourns Special Meeting of Shareholders to Permit Further Solicitation of Proxies

Retrieved on: 
Tuesday, December 19, 2023

XAI Octagon Floating Rate & Alternative Income Term Trust (the “Trust”) (NYSE: XFLT) announced today that its special meeting of shareholders (the “Special Meeting”) has been adjourned to January 24, 2024 at 10:00 a.m. Central time with respect to all proposals to allow more time for shareholders to vote.

Key Points: 
  • XAI Octagon Floating Rate & Alternative Income Term Trust (the “Trust”) (NYSE: XFLT) announced today that its special meeting of shareholders (the “Special Meeting”) has been adjourned to January 24, 2024 at 10:00 a.m. Central time with respect to all proposals to allow more time for shareholders to vote.
  • The reconvened Special Meeting will be held at offices of the Trust’s investment adviser, XA Investments LLC, 321 North Clark Street, Suite 2430, Chicago, Illinois 60654.
  • The October 25, 2023 record date for shareholders entitled to vote at the adjourned Special Meeting remains unchanged.
  • At the time the Special Meeting was adjourned, proxies had been submitted by shareholders representing approximately 40.35% of the Trust’s shares outstanding and entitled to vote.

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders

Retrieved on: 
Wednesday, October 11, 2023

The adjourned Special Meeting will reconvene on October 19, 2023 at 11:00 a.m. Eastern Time at https://www.viewproxy.com/vynt/2023 .

Key Points: 
  • The adjourned Special Meeting will reconvene on October 19, 2023 at 11:00 a.m. Eastern Time at https://www.viewproxy.com/vynt/2023 .
  • The record date of August 4, 2023 for the adjourned Special Meeting remains the same.
  • Stockholders of record may attend the virtual webcast meeting by logging in through the same method.
  • Stockholders who have already voted their shares on the proposals contained in the Proxy Statement do not need to vote again.

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Retrieved on: 
Tuesday, August 8, 2023

The August 25, 2023 meeting date replaces the previously announced August 11, 2023 date for the reconvened meeting and will be a “virtual” meeting of stockholders.

Key Points: 
  • The August 25, 2023 meeting date replaces the previously announced August 11, 2023 date for the reconvened meeting and will be a “virtual” meeting of stockholders.
  • The record date for the adjourned Annual Meeting continues to be April 17, 2023.
  • Vote at the virtual Annual Meeting by joining the meeting at https://web.lumiagm.com/236626312 (password: zyne2023) using the control number included on the proxy card.
  • Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting.

EQS-News: Iute Group EUR 2021/2026 bondholders with great consent to amend terms and conditions – Bondholders’ Meeting secures greater financial flexibility for growth

Retrieved on: 
Friday, August 4, 2023

Iute Group, a leading European personal finance group, through its fully owned subsidiary IuteCredit Finance S.à r.l., has received great consent from bondholders to amend the terms and conditions of its EUR 2021/2026 bonds (ISIN: XS2378483494).

Key Points: 
  • Iute Group, a leading European personal finance group, through its fully owned subsidiary IuteCredit Finance S.à r.l., has received great consent from bondholders to amend the terms and conditions of its EUR 2021/2026 bonds (ISIN: XS2378483494).
  • The participants voted with 95% almost unanimously in favor of each of the resolutions, thereby also duly meeting the majority thresholds.
  • Tarmo Sild, Group CEO: “We thank the bondholders for their trust in Iute.
  • Iute grows and develops thanks to joint efforts, in which the people who invest their money in Iute play a major role.

NIKOLA STOCKHOLDER MEETING: PROPOSAL 2 PASSES

Retrieved on: 
Thursday, August 3, 2023

PHOENIX, Aug. 3, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy infrastructure supply and solutions, today announced that Nikola has received the requisite number of votes to elect all nominees for director and approve each of the other proposals, including a sufficient number of shares voted in favor of Proposal 2, the Amendment to the Second Amended and Restated Certificate of Incorporation to Increase the authorized number of shares of common stock.

Key Points: 
  • PHOENIX, Aug. 3, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy infrastructure supply and solutions, today announced that Nikola has received the requisite number of votes to elect all nominees for director and approve each of the other proposals, including a sufficient number of shares voted in favor of Proposal 2, the Amendment to the Second Amended and Restated Certificate of Incorporation to Increase the authorized number of shares of common stock.
  • "We are immensely grateful for the unwavering support and confidence our stockholders have demonstrated in Nikola with the passage of all of this year's Proposals," expressed Michael Lohscheller, Nikola's Chief Executive Officer.
  • "This positive outcome, particularly with respect to Proposal 2, was critical for continued growth and success as we move forward with our strategic priorities, including autonomous technologies and software, our HYLA hydrogen ecosystem and the recent launch of the Nikola hydrogen fuel cell electric vehicle."

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Retrieved on: 
Tuesday, July 25, 2023

The August 11, 2023 meeting date replaces the previously announced July 27, 2023 date for the reconvened meeting and will be a “virtual” meeting of stockholders.

Key Points: 
  • The August 11, 2023 meeting date replaces the previously announced July 27, 2023 date for the reconvened meeting and will be a “virtual” meeting of stockholders.
  • The record date for the adjourned Annual Meeting continues to be April 17, 2023.
  • Vote at the virtual Annual Meeting by joining the meeting at https://web.lumiagm.com/236626312 (password: zyne2023) using the control number included on the proxy card.
  • Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting.

EQS-News: Iute initiates process to amend terms and conditions of EUR 2021/2026 bonds – Invitation to Bondholders’ Meeting on 3 August 2023

Retrieved on: 
Thursday, July 13, 2023

Iute Group, a leading European personal finance group, through its fully owned subsidiary IuteCredit Finance S.à r.l., has initiated the formal process to amend the terms and conditions of its EUR 2021/2026 bonds (ISIN: XS2378483494).

Key Points: 
  • Iute Group, a leading European personal finance group, through its fully owned subsidiary IuteCredit Finance S.à r.l., has initiated the formal process to amend the terms and conditions of its EUR 2021/2026 bonds (ISIN: XS2378483494).
  • The above resolution proposals constitute a Uniform Resolution Proposal and will therefore only be voted uniformly on as a Uniform Resolution Proposal.
  • The results of the voting will be available on the Group’s website subsequent to the meeting of the bondholders.
  • Holders of EUR 2021/2026 bonds are encouraged to reach out directly to Aalto Capital for more information regarding the process for amending the terms and conditions of the bonds:

NIKOLA ADJOURNS AND WILL RECONVENE ANNUAL MEETING OF STOCKHOLDERS ON AUGUST 3, 2023

Retrieved on: 
Thursday, July 6, 2023

PHOENIX, July 6, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, today announced that its 2023 Annual Meeting of Stockholders has been adjourned to August 3, 2023 at 1:00 p.m., Pacific Time.

Key Points: 
  • PHOENIX, July 6, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, today announced that its 2023 Annual Meeting of Stockholders has been adjourned to August 3, 2023 at 1:00 p.m., Pacific Time.
  • A proposed amendment to Section 242 of the Delaware General Corporation Law is expected to be effective August 1, 2023.
  • Stockholders must ACTIVELY VOTE by 11:59 p.m., Eastern Time, on August 2, 2023, for their vote to count.
  • The 2023 Annual Meeting of Stockholders will be held virtually on Thursday, August 3, 2023, at 1:00 p.m., Pacific Time via live audio webcast.

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting

Retrieved on: 
Wednesday, June 28, 2023

DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time to consider and vote on Proposal 2 to amend the Sixth Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split of the Company’s outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-50, at any time prior to November 1, 2023, the implementation and timing of which shall be subject to the discretion of the Board of Directors of the Company.

Key Points: 
  • The Annual Meeting will be reconvened on July 27, 2023 at 9:00 am EDT, and will be a “virtual” meeting of stockholders.
  • The record date for the adjourned Annual Meeting continues to be April 17, 2023.
  • Vote at the virtual Annual Meeting by joining the meeting at https://web.lumiagm.com/236626312 (password: zyne2023) using the control number included on the proxy card.
  • Details of the reverse stock split are included in the Company’s Proxy Statement for the Annual Meeting.